Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains an Overweight rating on Cytek Biosciences (NASDAQ:CTKB) but lowers the price target from $8.5 to $8.
August 13, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler analyst David Westenberg maintains an Overweight rating on Cytek Biosciences but lowers the price target from $8.5 to $8.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100